Citi's economist discusses Fed's interest rate decisions. Bank of America predicts a soft landing post high rates. Moderna CEO talks about better-than-expected earnings and RSV vaccine development.
Inflation data may prompt Fed to cut rates, US market poised for soft landing.
AI enhances drug development, accelerates clinical phases, and revolutionizes Moderna's processes.
Deep dives
Analysis of the Market Cycle and Inflation
The speaker discusses the current position in the market cycle, suggesting a potential shift to a soft landing scenario. They highlight factors such as demographic trends and structural shifts impacting the labor market dynamics. The conversation delves into the presence of healthier inflation levels and the potential impact of higher interest rates on equity performance.
Challenges and Opportunities for Different Economic Segments
The conversation touches on the income gap widening and the potential effects of inflation on various economic segments. It explores the positive impact of reshoring on manufacturing jobs in the US and the implications of higher oil prices. Additionally, the discussion considers the US's energy independence as a factor in mitigating potential risks.
Use of Artificial Intelligence in Drug Development
The episode shifts focus to drug development, emphasizing the role of artificial intelligence in expediting the process. Specifically, the guest explains how AI accelerates the understanding of human biology, aids in drug discovery, and enhances productivity in clinical development phases. The discussion also includes examples of AI applications within Moderna, highlighting its potential to revolutionize drug development timelines.
-Andrew Hollenhorst, Citi Chief US Economist -Savita Subramanian, Bank of America Head of US Equity & Quantitative Strategy -Stephane Bancel, Moderna CEO
Citi's Andrew Hollenhorst reacts to the Fed's decision to hold interest rates, saying inflation data will give the Fed the opportunity to cut rates this year. BofA's Savita Subramanian says the US will achieve a soft landing where the market adapts to higher rates. Moderna CEO Stephane Bancel reacts to better-than-expected first quarter earnings and discusses the company's upcoming RSV vaccine.